Literature DB >> 22421688

National estimates of seroincidence and seroprevalence for herpes simplex virus type 1 and type 2 among US military adults aged 18 to 29 years.

William F Page1, Mikayla Chubb, Xiaoshu Feng, Lynn Y Fan, Yuanzhang Li, Natalya S Weber, Lynn I Levin, David W Niebuhr.   

Abstract

BACKGROUND: While population-based seroprevalence studies of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) are widespread, seroincidence studies are largely limited to select or high-risk populations. The US military offers a potential population to derive national seroincidence rate estimates for young adults (ages 18-29).
METHODS: We used banked, longitudinal serum specimens collected in a cohort of 1094 military personnel aged 18 to 30 years who served between 1989 and 2005 to estimate national HSV-1 and HSV-2 seroincidence and seroprevalence for the young, adult military population, weighted according to the US Census. Serum was tested with indirect ELISA (enzyme-linked immunosorbent assay).
RESULTS: Estimated national seroincidence rates for the US young, adult military population were 9.1 per 100 person-years (95% confidence interval: 4.6-13.5) for HSV-1 and 6.2 (95% confidence interval: 3.1-9.3) for HSV-2. Female sex and black race were associated with significantly higher HSV-2 seroconversion rates. Our estimated HSV1/2 seroprevalences were comparable to US national data provided by National Health and Nutrition Examination Surveys' serosurveys except for non-Hispanic blacks and Hispanics.
CONCLUSION: Although these US 2000 Census-weighted estimates of HSV-1 and HSV-2 seroincidence apply only to young, military adults, they nonetheless supply, to our knowledge, the only national figures that might be used to predict US national HSV1/2 seroincidence in young adults. Thus, we believe that our findings in this military population can be used to inform the planning of HSV-1 and 2 prevention measures in the general, young-adult US population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22421688     DOI: 10.1097/OLQ.0b013e3182401a17

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  5 in total

1.  Seroprevalence and seroincidence of herpes simplex virus (2006-2010), syphilis (2006-2010), and vaccine-preventable human papillomavirus subtypes (2000-2010) among US military personnel.

Authors:  Jennifer Masel; Robert G Deiss; Xun Wang; Jose L Sanchez; Anuradha Ganesan; Grace E Macalino; Joel C Gaydos; Mark G Kortepeter; Brian K Agan
Journal:  Sex Transm Dis       Date:  2015-05       Impact factor: 2.830

2.  Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal Epidemiology Working Group.

Authors:  Birte Holtfreter; Jasim M Albandar; Thomas Dietrich; Bruce A Dye; Kenneth A Eaton; Paul I Eke; Panos N Papapanou; Thomas Kocher
Journal:  J Clin Periodontol       Date:  2015-05-07       Impact factor: 8.728

3.  Population and dyadic-based seroincidence of herpes simplex virus-2 and syphilis in southern India.

Authors:  Chad H Hochberg; John A Schneider; Rakhi Dandona; Vemu Lakshmi; G Anil Kumar; Talasila Sudha; Mohammed Akbar; G Md Mushtaq Ahmed; Sri P Ramgopal; Benjamin Armbruster; Michel Alary; Lalit Dandona
Journal:  Sex Transm Infect       Date:  2015-01-20       Impact factor: 3.519

Review 4.  Description and utilization of the United States department of defense serum repository: a review of published studies, 1985-2012.

Authors:  Christopher L Perdue; Angelia A Eick Cost; Mark V Rubertone; Luther E Lindler; Sharon L Ludwig
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

5.  Prevalence and factors associated with herpes simplex virus type 2 infection in patients attending a Baltimore City emergency department.

Authors:  Eshan U Patel; Melanie A Frank; Yu-Hsiang Hsieh; Richard E Rothman; Amy E O Baker; Chadd K Kraus; Judy Shahan; Charlotte A Gaydos; Gabor D Kelen; Thomas C Quinn; Oliver Laeyendecker
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.